Crysvita (burosumab-twza) / Ultragenyx, Kyowa Kirin 
Welcome,         Profile    Billing    Logout  
 23 Diseases   6 Trials   6 Trials   545 News 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Crysvita (burosumab-twza) / Ultragenyx, Kyowa Kirin
NCT04419363: Burosumab in Children and Adolescents With X-linked Hypophosphatemia

Recruiting
4
57
Europe
Burosumab Injection
Bicetre Hospital
Rare Diseases, X-linked Hypophosphatemia
03/19
09/22
NCT04842019: Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH

Completed
4
18
RoW
KRN23, Burosumab, Crysvita
Kyowa Kirin Co., Ltd.
X-linked Hypophosphatemia (XLH)
08/23
08/23
NCT04842032: Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH

Completed
4
28
RoW
KRN23, Burosumab, Crysvita
Kyowa Kirin Co., Ltd.
X-linked Hypophosphatemia (XLH)
12/23
12/23
NCT05357573: Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO

Completed
4
9
RoW
KRN23, Burosumab, Crysvita
Kyowa Kirin Co., Ltd.
Tumor-Induced Osteomalacia (TIO)
11/23
12/23
BurGER, NCT04695860: Anti-FGF23 (Burosumab) in Adult Patients With XLH

Completed
3b
36
Europe
Burosumab
Wuerzburg University Hospital, Kyowa Kirin, Inc.
X-linked Hypophosphatemia
03/23
03/23
2019-003190-26: A study to test an antibody (Antibody Burosumab (KRN23)) to treat Hypophosphatemiazu (decreased phosphat level in the blood) in adults Eine Studie, um den Effekt eines Antikörpers (Burosumab (KRN23)) bei der Anwendung in erwachsenen Patienten mit Hypophosphatämie (zu niedriger Phosphatspiegel im Blut) zu testen

Not yet recruiting
3
34
Europe
Crysvita, Solution for injection, Crysvita
Julius-Maximilian University of Würzburg, Kyowa Kirin GmbH
X-linked hypophosphatemia (XLH) is a disorder of renal phosphate wasting, and the most common heritable form of rickets. In XLH patients, high circulating levels of fibroblast growth factor 23 (FGF23) impair normal phosphate reabsorption in the kidney. Low serum phosphorus levels result in hypomineralization of bone and associated abnormalities including rickets, bowing of the legs, and short stature. X-chromosomale Hypophosphatämie (XLH) ist eine Störung der Nierenphosphatverschwendung und die häufigste vererbbare Form von Rachitis. Bei XLH-Patienten beeinträchtigen hohe zirkulierende Spiegel des Fibroblasten-Wachstumsfaktors 23 (FGF23) die normale Phosphat-Reabsorption in der Niere. Niedrige Serumphosphorspiegel führen zu einer Hypomineralisierung des Knochens und damit verbundenen Anomalien wie Rachitis, Beugung der Beine und Kleinwuchs., The disease leads to a low phosphate level in the blood and thus to a demineralization of the bones with associated malformations in bones. Die Krankheit zeigt einen niedrigen Phosphatspiegel im Blut und führt zu einer Demineralisierung der Knochen mit damit verbundenen Fehlbildungen bei Knochen., Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT05509595: Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia

Active, not recruiting
2
12
US
Burosumab
National Institute of Dental and Craniofacial Research (NIDCR)
Fibrous Dysplasia Of Bone
09/30
09/30
NCT04188964 / 2019-000469-19: Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age

Completed
1/2
16
Europe
Burosumab, KRN23, Crysvita
Kyowa Kirin Pharmaceutical Development Ltd
X-linked Hypophosphatemia (XLH)
10/23
03/24
NCT03993821: Burosumab for CSHS

Active, not recruiting
1
1
US
Burosumab, Crysvita
Laura Tosi, Children's National Research Institute, Ultragenyx Pharmaceutical Inc
Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome
10/22
03/23
NCT06202027: Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients

Recruiting
N/A
100
RoW
FGF23-related hypophosphataemic rickets and osteomalacia
Kyowa Kirin Korea Co., Ltd.
FGF23-related Hypophosphataemic Rickets and Osteomalacia
06/31
07/31
NCT03775187: Expanded Access to Burosumab

Available
N/A
NA
Burosumab, UX023, Crysvita®, KRN23
Kyowa Kirin Co., Ltd., Kyowa Kirin Co., Ltd.
X-linked Hypophosphatemia, Tumor-Induced Osteomalacia
 
 
NCT05181839: A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth

Completed
N/A
25
Europe
Burosumab
Kyowa Kirin Pharmaceutical Development Ltd
X-Linked Hypophosphatemia
05/24
05/24
FLAM-XLH, NCT06248632: Effect of Burosumab on the Inflammatory Profile of Patients With X-linked Hypophosphatemic Rickets

Not yet recruiting
N/A
20
NA
Expression of inflammatory markers (Il6, Il8, Il1β, CXCL1, CCL2, CXCR3, Il1R, Il6R)
Hospices Civils de Lyon
X-Linked Hypophosphatemic Rickets
04/25
04/25
HYPO-BLASTE, NCT04159675: Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts

Recruiting
N/A
20
Europe
osteoblast biology study
Hospices Civils de Lyon
Craniosynostoses
04/26
04/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Crysvita (burosumab-twza) / Ultragenyx, Kyowa Kirin
NCT04419363: Burosumab in Children and Adolescents With X-linked Hypophosphatemia

Recruiting
4
57
Europe
Burosumab Injection
Bicetre Hospital
Rare Diseases, X-linked Hypophosphatemia
03/19
09/22
NCT04842019: Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH

Completed
4
18
RoW
KRN23, Burosumab, Crysvita
Kyowa Kirin Co., Ltd.
X-linked Hypophosphatemia (XLH)
08/23
08/23
NCT04842032: Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH

Completed
4
28
RoW
KRN23, Burosumab, Crysvita
Kyowa Kirin Co., Ltd.
X-linked Hypophosphatemia (XLH)
12/23
12/23
NCT05357573: Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO

Completed
4
9
RoW
KRN23, Burosumab, Crysvita
Kyowa Kirin Co., Ltd.
Tumor-Induced Osteomalacia (TIO)
11/23
12/23
BurGER, NCT04695860: Anti-FGF23 (Burosumab) in Adult Patients With XLH

Completed
3b
36
Europe
Burosumab
Wuerzburg University Hospital, Kyowa Kirin, Inc.
X-linked Hypophosphatemia
03/23
03/23
2019-003190-26: A study to test an antibody (Antibody Burosumab (KRN23)) to treat Hypophosphatemiazu (decreased phosphat level in the blood) in adults Eine Studie, um den Effekt eines Antikörpers (Burosumab (KRN23)) bei der Anwendung in erwachsenen Patienten mit Hypophosphatämie (zu niedriger Phosphatspiegel im Blut) zu testen

Not yet recruiting
3
34
Europe
Crysvita, Solution for injection, Crysvita
Julius-Maximilian University of Würzburg, Kyowa Kirin GmbH
X-linked hypophosphatemia (XLH) is a disorder of renal phosphate wasting, and the most common heritable form of rickets. In XLH patients, high circulating levels of fibroblast growth factor 23 (FGF23) impair normal phosphate reabsorption in the kidney. Low serum phosphorus levels result in hypomineralization of bone and associated abnormalities including rickets, bowing of the legs, and short stature. X-chromosomale Hypophosphatämie (XLH) ist eine Störung der Nierenphosphatverschwendung und die häufigste vererbbare Form von Rachitis. Bei XLH-Patienten beeinträchtigen hohe zirkulierende Spiegel des Fibroblasten-Wachstumsfaktors 23 (FGF23) die normale Phosphat-Reabsorption in der Niere. Niedrige Serumphosphorspiegel führen zu einer Hypomineralisierung des Knochens und damit verbundenen Anomalien wie Rachitis, Beugung der Beine und Kleinwuchs., The disease leads to a low phosphate level in the blood and thus to a demineralization of the bones with associated malformations in bones. Die Krankheit zeigt einen niedrigen Phosphatspiegel im Blut und führt zu einer Demineralisierung der Knochen mit damit verbundenen Fehlbildungen bei Knochen., Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT05509595: Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia

Active, not recruiting
2
12
US
Burosumab
National Institute of Dental and Craniofacial Research (NIDCR)
Fibrous Dysplasia Of Bone
09/30
09/30
NCT04188964 / 2019-000469-19: Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age

Completed
1/2
16
Europe
Burosumab, KRN23, Crysvita
Kyowa Kirin Pharmaceutical Development Ltd
X-linked Hypophosphatemia (XLH)
10/23
03/24
NCT03993821: Burosumab for CSHS

Active, not recruiting
1
1
US
Burosumab, Crysvita
Laura Tosi, Children's National Research Institute, Ultragenyx Pharmaceutical Inc
Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome
10/22
03/23
NCT06202027: Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients

Recruiting
N/A
100
RoW
FGF23-related hypophosphataemic rickets and osteomalacia
Kyowa Kirin Korea Co., Ltd.
FGF23-related Hypophosphataemic Rickets and Osteomalacia
06/31
07/31
NCT03775187: Expanded Access to Burosumab

Available
N/A
NA
Burosumab, UX023, Crysvita®, KRN23
Kyowa Kirin Co., Ltd., Kyowa Kirin Co., Ltd.
X-linked Hypophosphatemia, Tumor-Induced Osteomalacia
 
 
NCT05181839: A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth

Completed
N/A
25
Europe
Burosumab
Kyowa Kirin Pharmaceutical Development Ltd
X-Linked Hypophosphatemia
05/24
05/24
FLAM-XLH, NCT06248632: Effect of Burosumab on the Inflammatory Profile of Patients With X-linked Hypophosphatemic Rickets

Not yet recruiting
N/A
20
NA
Expression of inflammatory markers (Il6, Il8, Il1β, CXCL1, CCL2, CXCR3, Il1R, Il6R)
Hospices Civils de Lyon
X-Linked Hypophosphatemic Rickets
04/25
04/25
HYPO-BLASTE, NCT04159675: Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts

Recruiting
N/A
20
Europe
osteoblast biology study
Hospices Civils de Lyon
Craniosynostoses
04/26
04/26

Download Options